Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2014—Currently in development from Abbott is the Iridica platform, targeted for release in CE-marked European countries within 12 months, to test for and identify hundreds of bacteria and candida, fungi, and viruses from a direct patient specimen.
September 2014—Atomo Diagnostics introduced the AtomoRapid all-in-one blood test. It can accommodate test strips for a variety of conditions, from celiac disease and allergies to infectious diseases, such as malaria and HIV.
September 2014—Beckman Coulter Diagnostics showcased five laboratory solutions in its booth, which was themed “New Laboratory Challenges Require New Thinking”: the Power Express automation solution consolidates immunoassay, hematology, and coagulation; the DxH Connected Workcell offers labs workflow management while delivering comprehensive and accurate patient results; the latest addition of the IRIS International urinalysis portfolio; the Remisol Advance enterprise data management system; and its immunoassay diagnostic testing menu, which includes AccuTnI+3 troponin I in the cardiac panel, the Prostate Health Index (phi) as part of the men’s health panel, and a complete reproductive panel.
September 2014—Multisorb’s QbD-based Calculations through Operations program provides an effective and efficient solution for ensuring the chemical and physical stability of IVD devices through their desired shelf life.
September 2014—Orchard Software has introduced Orchard Sequoia, a laboratory information system for the enterprise-wide lab. Sequoia is “designed to be scalable and to address the needs of the largest clients,” says Rob Bush, president of Orchard Software. The product’s three-tier design accommodates the needs of high-volume laboratories across multiple locations and departments, including clinical, molecular, anatomic pathology, and microbiology.
September 2014—Sysmex America displayed four new products at its booth. The DI-60 Integrated Slide Processing System provides automation of manual WBC differential process in a stand-alone configuration, offering a cell image analyzer for any type of laboratory or budget.
September 2014—The Binding Site announced an enhancement to its Rheumatoid Factor/Immunoglobulin-G Absorbent Reagent specifically designed for use in conjunction with infectious disease immunodiagnostic procedures. The RF/IgG Absorbent Reagent can now be used to equally test and analyze serum and plasma samples without compromising test results.
September 2014—Medical experts representing Vermillion, a multivariate diagnostics company focused on gynecologic cancers and women’s health, presented on Aspira Labs, its new CLIA-certified reference laboratory. Aspira Labs provides expert diagnostic services, including OVA1 and Longitudinal CA 125 testing, which support clinical decision-making and personalized treatment plans.
September 2014—UniConnect announced the release of its PrecisionMDx System for molecular laboratories. The system has been developed for laboratory professionals seeking a focused solution for CAP- and CLIA-certified molecular laboratory operations, and the software platform is ideal for MDx, CDx, and PGx pursuits.
September 2014—Pall Life Sciences’ Acrodisc WBC premium syringe filter is a filtration device designed specifically for use in the capture and recovery of leukocytes and the separation of red blood cells. The Acrodisc WBC filter contains the company’s patented Leukosorb media.
